My assessment of Arcellx ( ACLX ) leads me to a very optimistic conclusion: This is not simply one more CAR T firm competing in the multiple myeloma space. In my opinion, Arcellx is creating a commercially viable, scalable, andI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamental analysis and future ...